Innovative science

We have applied our insights into the structure and biological function of individual PI3K and HDAC enzymes to de novo-design and develop innovative new cancer drugs with significant clinical potential. Our PI3K-p110β/δ-selective inhibitor, KA2237, is in Phase I in patients with B-cell lymphoma. Our selective HDAC6 inhibitor, KA2507, is entering Phase I trials in patients with solid tumors.

Read more »

Clinical pipeline

We are collaborating with The University of Texas MD Anderson Cancer Center, which is conducting the Phase I clinical trials for KA2237 and KA2507 in patients with B-cell lymphoma and PD-L1-expressing solid tumors, respectively.

KA2237 – Phase I

KA2237 is a potent, dual-selective inhibitor of the p110β and p110δ isoforms of PI3K. This drug has a combined targeted and immunotherapeutic mode of action. It inhibits oncogenic pathways within cancer cells, and drives immunotherapeutic activity within the tumor microenvironment. Its selectivity for p110β and p110δ reduces the potential for side effects connected to p110α and p110γ inhibition.

Read more »

KA2507 – Phase I

KA2507 is a potent and selective inhibitor of HDAC6. Selective HDAC6 inhibition promotes tumor cell apoptosis by suppressing aggresome formation and also drives immunotherapeutic inhibition of cancer cell proliferation by modulating key tumor microenvironment markers, including by downregulating the expression of programmed death ligand-1 (PD-L1).

Read more »

Press Releases

  • 21 October 2016
    Karus Therapeutics presenting at BIO-Europe
    Read more »
  • 05 October 2016
    Karus Therapeutics Announces First Lymphoma Patients Dosed with KA2237 in Clinical Study at the MD Anderson Cancer Center
    Read more »
  • 03 October 2016
    Karus Therapeutics giving lecture at BIO Investor
    Read more »

In The News

  • 04 November 2016
    Karus Therapeutics features in BioCentury Innovations
    Read more »
  • 15 May 2014
    Karus Therapeutics features in SciBX
    Read more »
  • 25 February 2014
    Karus Therapeutics showcased in BVCA’s Britain’s Hot Talents 2014/15
    Read more »